Med. Pro Praxi 2004; 1: 33-36

Nová perorální antidiabetika

doc. MUDr. Tomáš Sechser CSc
Pracoviště klinické farmakologie Centra diabetologie IKEM Praha

Keywords: perorální antidiabetika, biguanidy, deriváty sulfonylurey, meglitinidy, thiazolidindiony.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sechser T. Nová perorální antidiabetika. Med. praxi. 2004;2(1):33-36.

Léčba perorálními antidiabetiky je nedílnou součástí komplexní léčby diabetiků 2. typu. Skupina perorálních antidiabetik, která jsou u nás k dispozici, se stále rozšiřuje. Vedle -klasických- biguanidů a derivátů sulfonylurey, které zůstávají základními kameny farmakoterapie diabetiků 2. typu, vstupují na náš farmaceutický trh zcela nové skupiny: meglitinidy a thiazolidindiony (glitazony). Zařazování těchto slibných farmak do komplexní terapeutické intervence diabetiků je ovšem spojeno s vyššími přímými náklady na léčbu a tím i nutně s vyššími nároky na jejich skutečně racionální používání.

Pracoviště klinické farmakologie Centra diabetologie

Institutu klinické a experimentální medicíny, Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Diabetes Association. Implication of the United Kindom prospective study. Diabetes Care 1998; 21: 2180-2184. Go to original source... Go to PubMed...
    2. Bartoš V, Pelikánová T, et al. Praktická diabetologie. Praha, Maxdorf, 2000.
    3. Cerasi E. Editorial: Type 2 diabetes: to stimulate or not to stimulate the ? cell. Metabolism 2000; 49 (Suppl. 2): 1-2. Go to original source...
    4. Chehade JM, Mooradian AS. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000; 60: 95-113. Go to original source... Go to PubMed...
    5. Chlup R. Diabetes mellitus a onemocnění kardiovaskulárního systému - II. Patogeneticky podložená prevence a léčba. Interní medicína pro praxi 2002; 10:486-493.
    6. Costa B, Arroyo J, Sabaté A. The economics of pharmacotherapy for diabetes mellitus. PharmacoEconomics 1997; 11: 139-158. Go to original source... Go to PubMed...
    7. De Fronzo RA. Pharmacologic therapy for type 2 diabetics mellitus. Ann. Intern Med 1999; 131: 281-303. Go to original source... Go to PubMed...
    8. Drug treatment of type 2 diabetes. Ed. Andrew J.Krentz. Adis International Limited, 2000: 101 s.
    9. European Diabetes Policy Group 1998-1999: Guidelines for Diabetes Care. A Desktop Guide to Type 2 Diabetes mellitus. International Diabetes Federation, European Region, Brussels. Diabetic Medicine 1999; 16: 1-35. Go to original source...
    10. Pelikánová, T.: Syndrom inzulinové rezistence. Postgraduální medicína, 2002; 4: 7-13.
    11. Scheen AJ, Lefebre PJ. Oral antidiabetic Agents. A guide to selection. Drugs 1998; 55: 225-236. Go to original source... Go to PubMed...
    12. Testa MA, Simonson DC: Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. A randomized, controlled, double-blind trial. JAMA 1998; 280: 1490-1496. Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.